April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
Adalimumab (humira) For The Treatment Of Refractory Sight-threatening Non-infectious Uveitis: One Year Outcomes Of An Open-label Prospective Multicenter Study
Author Affiliations & Notes
  • Eric B. Suhler
    Uveitis Clinic/Portland VAMC,
    Casey Eye Institute-OHSU, Portland, Oregon
  • Careen Y. Lowder
    Cole Eye Inst-Ophthalmology, Cole Eye Institute, Cleveland, Ohio
  • Debra A. Goldstein
    Ophthalmology, Univ of Illinois at Chicago, Chicago, Illinois
  • Tracy R. Giles
    Uveitis Clinic/Portland VAMC,
    Casey Eye Institute-OHSU, Portland, Oregon
  • Howard H. Tessler
    Department of Ophthalmology, University of Illinois, Gurnee, Illinois
  • Andreas K. Lauer
    Casey Eye Institute, Oregon Health Sciences University, Portland, Oregon
  • Justine R. Smith
    Casey Eye Inst Biomed Res Bldg, Oregon Health Sciences Univ, Portland, Oregon
  • James T. Rosenbaum
    Casey Eye Institute-OHSU, Portland, Oregon
  • Footnotes
    Commercial Relationships  Eric B. Suhler, Abbott (F); Careen Y. Lowder, Abbott (F); Debra A. Goldstein, Abbott (F); Tracy R. Giles, Abbott (F); Howard H. Tessler, Abbott (F); Andreas K. Lauer, Abbott (F); Justine R. Smith, Abbott (F); James T. Rosenbaum, Abbott (F)
  • Footnotes
    Support  RPB (to Casey Eye Institute, JTR, JRS), Dept. of Veterans' Affairs (EBS), and Abbott
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 6565. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Eric B. Suhler, Careen Y. Lowder, Debra A. Goldstein, Tracy R. Giles, Howard H. Tessler, Andreas K. Lauer, Justine R. Smith, James T. Rosenbaum; Adalimumab (humira) For The Treatment Of Refractory Sight-threatening Non-infectious Uveitis: One Year Outcomes Of An Open-label Prospective Multicenter Study. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6565.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : to report one year safety and effectiveness outcomes of adalimumab (Humira, Abbott), a fully human monoclonal antibody against TNF-alpha, for the treatment of refractory non-infectious uveitis.

Methods: : Three centers received IRB approval to participate in an open-label, prospective clinical trial utilizing 40 mg subcutaneous adalimumab injections given every two weeks for non-infectious uveitis refractory to corticosteroids and at least one immunosuppressive. Treatment outcome was ascertained at 10 weeks by a composite clinical endpoint comprised of visual acuity, intraocular inflammation, ability to taper corticosteroids or immunosuppressives, and posterior segment imaging with fluorescein angiography and ocular coherence tomography. Patients who met one or more study endpoints without decrement in any were allowed to continue adalimumab for a total of 50 weeks, when final outcome assessments were obtained.

Results: : 31 patients were enrolled from February 2008 to September 2009. Twenty-one of 31 patients (68%) were characterized as clinical responders at 10 weeks and allowed to continue in the study. Thirteen of 21 (62%) initial responders exhibited durable response to adalimumab therapy at the 50 week endpoint. Reasons for study discontinuation after 10 weeks were unintended pregnancy (1), loss to followup (1), and primary loss of efficacy (6). One significant adverse effect, in which a patient was hospitalized in a hypoglycemic coma, required study discontinuation, but was not clearly related to adalimumab. Minor adverse effects included mild infections that required delaying adalimumab injections but that did not require study discontinuation.

Conclusions: : Adalimumab was effective in 68% of enrolled patients with refractory uveitis 10 weeks after study enrollment, with 13 of 31 enrolled patients (42%) maintaining benefit after one year. Significant toxicity was uncommon. Ongoing study is required to determine the role of TNF-alpha blockers in general, and adalimumab specifically, in patients with refractory ocular inflammatory disease.

Clinical Trial: : http://www.clinicaltrials.gov NCT00525902

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • inflammation • immunomodulation/immunoregulation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.